SAGE Therapeutics is currently developing their lead program, SAGE-547, for super refractory status epilepticus, along with other compounds in their portfolio for potential seizure medicines. They are also working on programs in neuroanesthesia and orphan genetic CNS disorders where current therapies are inadequate. Their goal is to pioneer solutions that improve brain health and transform the lives of people with debilitating brain disorders.